How might shockwaves relieve pain? A 2009 debate · Lab study · 2009
How might shockwave ease pain?
This short expert letter argues that shockwave eases pain mainly through effects on nerves in the treated tissue, rather than through a "pain memory" in the brain and spinal cord. It points to animal studies in which shockwave changed pain-signalling substances and reduced some small pain fibres.
Explores how shockwave may ease pain- year this letter was published
- 2009
- conditions discussed: heel, Achilles and outer elbow
- 3
- new patients; it reviews earlier research
- 0
Good to know: A letter, not a new study; it cites earlier trials and animal research. Both authors were linked to a shockwave device maker.
Schmitz C, DePace R Urol Res, 2009 · Read the paper ↗
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
Who took part
No new patients. The letter discusses heel, Achilles tendon and outer-elbow pain, citing studies in rabbits and rats.
Side effects
The letter warns that using shockwave on the heart without care could damage the lungs or block a blood vessel (embolism). These are warnings, not side effects counted in patients.
All the numbers and the full appraisal
Every reported result
What the full paper reports.
No new patient cohort. Discussion concerns plantar fascia, Achilles and lateral elbow entheses, with mechanistic evidence from rabbit femur and rat skin/neurons.
Proposed peripheral mechanisms1 reported outcome
Proposed peripheral mechanisms
Qualitative finding
Qualitative mechanisms: substance P release/depletion, reduced dorsal-root-ganglion immunoreactivity, CGRP changes and loss of unmyelinated fibers in animal work. No patient-level pain effect or pooled estimate is reported.
Analysis details and source
Qualitative extraction preserves the source scope.
Historical device regulation1 reported outcome
Historical device regulation
Qualitative finding
Polemic, selective citation and preclinical-to-clinical extrapolation; both authors are affiliated with EMS, a device manufacturer discussed favorably. Regulatory statements explicitly refer to February 2009 and cannot be treated as current approvals. No systematic search or risk-of-bias appraisal.
Analysis details and source
Qualitative extraction preserves the source scope.
How treatment was delivered
The letter warns that casual cardiac use may damage lung or cause embolism; these are cautions, not measured event rates in this report.
Polemic, selective citation and preclinical-to-clinical extrapolation; both authors are affiliated with EMS, a device manufacturer discussed favorably. Regulatory statements explicitly refer to February 2009 and cannot be treated as current approvals. No systematic search or risk-of-bias appraisal.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Polemic, selective citation and preclinical-to-clinical extrapolation; both authors are affiliated with EMS, a device manufacturer discussed favorably. Regulatory statements explicitly refer to February 2009 and cannot be treated as current approvals. No systematic search or risk-of-bias appraisal.
Source-linked critical reading
Letter to the editor
Technical source record
Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. External supplements not supplied with the intake were not read.
There are plausible biological explanations for pain relief, but this letter itself does not show how well a treatment works.
What evidence challenges a pain-memory explanation for ESWT analgesia?
2009 letter to the editor responding to Wess, not a trial or systematic review. It cites clinical trials, animal mechanisms and historical US device classifications selectively.
No new patient cohort. Discussion concerns plantar fascia, Achilles and lateral elbow entheses, with mechanistic evidence from rabbit femur and rat skin/neurons.
No treatment regimen is tested. The letter emphasizes device-specific evidence and anatomically targeted interventions rather than supplying a transferable dose.
The conceptual comparator is Wess’s associative pain-memory model; this is a scientific argument, not randomized comparison between devices or theories.
Qualitative mechanisms: substance P release/depletion, reduced dorsal-root-ganglion immunoreactivity, CGRP changes and loss of unmyelinated fibers in animal work. No patient-level pain effect or pooled estimate is reported.
Authors argue peripheral tissue and sensory-neuron mechanisms provide plausible explanations for analgesia. These observations do not prove the dominant mechanism in humans or invalidate all central contributions to pain.
The letter warns that casual cardiac use may damage lung or cause embolism; these are cautions, not measured event rates in this report.
Polemic, selective citation and preclinical-to-clinical extrapolation; both authors are affiliated with EMS, a device manufacturer discussed favorably. Regulatory statements explicitly refer to February 2009 and cannot be treated as current approvals. No systematic search or risk-of-bias appraisal.
Useful for understanding historical mechanistic debate and the need for indication/device-specific evidence. It cannot choose a current device or estimate an individual patient’s likely benefit.
Direct human mechanistic studies and independently assessed device-specific clinical trials should connect biological changes with sustained patient outcomes.
Read the original article.
Pain relief by extracorporeal shockwave therapy: an update on the current understanding
Schmitz C, DePace R. · Urol Res · 2009
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →